The Eighth Community Pharmacy Agreement (8CPA) supports the Australian Government in delivering its National Medicines Policy. It plays a vital role in ensuring patient access to Pharmaceutical Benefits Scheme (PBS) subsidized medicines and pharmacy health services through community pharmacies across Australia.
The 8CPA has an overall funding envelope of $26.44 billion comprising
for dispensing remuneration including $2.11 billion for new fees related to 60-day scripts
for programs including increases to DAA caps
for other policy commitments including extending a $1 reduction in co-payments to all Australians in place of the optional $1 discount
Reversing the damage of 60-day dispensing through structural change to dispensing remuneration
$2.11b for new fees related to 60-day dispensing
$4.88b increase in total funding from 7CPA (+22%), including a $3.94b increase in dispensing remuneration and a 35% increase in programs funding
Average PBS remuneration per script to increase year-on-year each year of 8CPA, and the dispense fee, Tier 1 AHI fee and dangerous drug fee to be indexed by CPI on 1 July each year
Co-payment indexation frozen, and patient co-payments to all reduce by $1, with current $1 discount to be gone by January 2029
DAA base cap increase from 60 to 90 per week
An additional $52 million for RPMA
Use the 8CPA Calculator to compare your remuneration for the final year of the 7CPA with the first year of the 8CPA.
Your 8CPA questions answered.
Check back regularly for more FAQs - or reach out if you have another question pbs.issues@guild.org.au